FOXM1–ERα ceRNA Network: Biomarker Axis in Female Lung Adenocarcinoma

Study Background and Research Question

Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, particularly among women, despite advances in targeted therapies. Estrogen receptor signaling is recognized as a contributing factor in the pathogenesis of female LUAD, yet the mechanistic interplay between hormone signaling, oncogenic transcription factors, and non-coding RNA networks is not fully elucidated. The reference study (Zhang et al., 2023) addresses this gap by investigating the role of the transcription factor FOXM1 and its regulatory interactions with ERα (estrogen receptor 1) within a competitive endogenous RNA (ceRNA) network context, aiming to identify novel biomarkers and therapeutic targets for female LUAD.

Key Innovation from the Reference Study

The principal innovation of the study lies in the identification and cellular validation of a ceRNA network involving FOXM1, ERα, has-miR-204-5p, and DGCR5 in female LUAD. By employing integrative bioinformatics and wet-lab validation, the authors demonstrate that this network not only regulates LUAD cell proliferation and apoptosis but also modulates immune sensitivity, with FOXM1 expression serving as a predictive marker for immunotherapy response. This directly links estrogen receptor signaling with LUAD tumor biology and immune landscape, a mechanistic axis previously underexplored in this cancer subtype (see reference).

Methods and Experimental Design Insights

The study utilized a comprehensive multi-omics approach:

• Transcriptomic Data Mining: Differential expression and survival analyses were performed using data from the Genomic Data Commons (TCGA) and Gene Expression Omnibus (GEO).
• ceRNA Network Construction: The authors predicted relevant microRNAs (miRNAs) targeting FOXM1 with miRDB, miRTarBase, and TargetScan, and constructed a ceRNA network (DGCR5—has-miR-204-5p—FOXM1—ERα) using Cytoscape.
• Cellular Validation: Knockdown experiments in LUAD cell lines assessed the impact of FOXM1 on proliferation and apoptosis, and confirmed the regulatory effect of has-miR-204-5p on FOXM1, but not DGCR5 as a direct target.
• Immune Landscape Analysis: The study evaluated tumor mutational burden (TMB) and immune cell infiltration using gene set enrichment analysis, correlating FOXM1 expression with sensitivity to immunotherapies.

This integrative design allowed robust cross-validation of bioinformatic predictions with cellular phenotypes, strengthening the translational relevance of the findings.

Core Findings and Why They Matter

Key discoveries from the study include:

• FOXM1 Overexpression in LUAD: LUAD tissues showed significantly higher FOXM1 expression compared to normal controls, consistent with FOXM1’s established role in cancer proliferation (reference).
• Prognostic Value: High FOXM1 levels correlated with poor overall survival and greater tumor progression in clinical cohorts.
• ceRNA Network Validation: The ceRNA axis—comprising DGCR5, has-miR-204-5p, FOXM1, and ERα—was confirmed, with has-miR-204-5p directly repressing FOXM1, and FOXM1 physically interacting with estrogen receptors.
• Immunotherapy Sensitivity: LUAD samples with low FOXM1 expression displayed enhanced sensitivity to immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4), indicating that FOXM1 status could help stratify patients likely to benefit from immunotherapy.

These findings position the FOXM1–ERα ceRNA network as both a mechanistic biomarker axis and a potential guide for personalized therapeutic strategies in female LUAD.

Comparison with Existing Internal Articles

Recent internal literature has emphasized the value of dissecting estrogen receptor alpha (ERα) biology using subtype-selective ligands and advanced bioinformatics. For example, the article "Unlocking Precision in Estrogen Receptor Alpha Research" contextualizes how PPT (Propyl Pyrazole Triol), a highly selective ERα agonist, enables the functional dissection of estrogen receptor signaling and ceRNA networks in cancer models. Similarly, "FOXM1–ERα ceRNA Network as a Biomarker Axis in Female LUAD" provides a focused discussion on the same biomarker network, underscoring the translational potential of targeting ERα-driven pathways. The present reference study extends these insights by directly validating the network components in LUAD and linking them to immunotherapy response, bridging mechanistic understanding with clinical application.

Limitations and Transferability

While the study’s integrative approach strengthens its conclusions, several limitations should be considered:

• Model System Constraints: Cellular validation was performed in specific LUAD cell lines, which may not capture the full heterogeneity of patient tumors.
• In Vivo Relevance: Although immune sensitivity was inferred from transcriptomic and mutational analyses, in vivo functional validation of FOXM1–ERα interactions in immunotherapy models is needed for translational certainty.
• Network Complexity: The ceRNA regulatory landscape is intricate; additional lncRNAs, miRNAs, and post-translational modifications may modulate the observed interactions.

Despite these limitations, the study offers a transferable workflow for biomarker discovery and mechanism-based stratification in hormone-driven cancers, with particular applicability to female LUAD.

Protocol Parameters

• FOXM1 knockdown: Use siRNA or shRNA targeting FOXM1; validate knockdown efficiency by qPCR and western blot after 48–72 hours in LUAD cell lines.
• miRNA modulation: Transfect has-miR-204-5p mimics or inhibitors to assess impact on FOXM1 mRNA/protein levels and downstream cellular phenotypes.
• ceRNA network validation: Employ luciferase reporter assays with FOXM1 3' UTR constructs to confirm miR-204-5p targeting; use RNA immunoprecipitation to test interactions with ERα.
• Immune sensitivity assays: Correlate FOXM1 expression with TMB and immune checkpoint gene expression using TCGA or in-house RNA-seq datasets.

These parameters reflect literature-backed protocols from the reference paper and can be adapted to similar mechanistic biomarker studies.

Research Support Resources

For researchers aiming to dissect ERα-mediated gene expression or validate estrogen receptor signaling within complex regulatory networks, PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist (SKU B6735) provides a reliable tool for subtype-selective ERα activation. As reported in the product information, PPT enables precise interrogation of ERα-specific pathways in both in vitro and in vivo models, facilitating advanced studies on hormone-driven gene regulation and biomarker network validation. This reagent is intended exclusively for research use and is not for diagnostic or therapeutic applications.